Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE‐100

Interim results from the two‐cohort, phase 2 KEYNOTE‐100 study (NCT02674061) of 376 patients with previously treated advanced recurrent ovarian cancer (ROC) showed that pembrolizumab monotherapy was associated with an objective response rate (ORR) of 8.0% (95% CI, 5.4‐11.2). We present outcomes for...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishio, Shin, Matsumoto, Koji, Takehara, Kazuhiro, Kawamura, Naoki, Hasegawa, Kosei, Takeshima, Nobuhiro, Aoki, Daisuke, Kamiura, Shoji, Arakawa, Atsushi, Kondo, Eiji, Hirakawa, Tomoko, Yamamoto, Keiko, Aoki, Masayuki, Stein, Karen, Keefe, Stephen, Fujiwara, Keiichi, Ushijima, Kimio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156846/
https://www.ncbi.nlm.nih.gov/pubmed/32012411
http://dx.doi.org/10.1111/cas.14340

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156846/
https://www.ncbi.nlm.nih.gov/pubmed/32012411
http://dx.doi.org/10.1111/cas.14340

Ejemplares similares